Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 190 (3), 565-70

Immune Responses to an Oral Typhoid Vaccine Strain That Is Modified to Constitutively Express Vi Capsular Polysaccharide

Affiliations
Clinical Trial

Immune Responses to an Oral Typhoid Vaccine Strain That Is Modified to Constitutively Express Vi Capsular Polysaccharide

Carol O Tacket et al. J Infect Dis.

Abstract

Protection against typhoid fever might be best achieved by a vaccine that stimulates IgG antibody to Vi capsular polysaccharide (Vi) in serum, IgG antibody to O antigen in serum, and cell-mediated immune responses. Live typhoid vaccines have not elicited anti-Vi antibody, presumably because Vi expression is highly regulated. CVD 909 is an oral attenuated typhoid vaccine candidate that is engineered to constitutively express Vi. In the present study, CVD 909, at doses of 10(6-9) cfu, was orally administered to 32 healthy adults, and immune responses were measured. Although many of the volunteers generated antibody-secreting cell responses to Vi, only 2 of the 32 volunteers generated anti-Vi IgG antibody in serum.

Similar articles

See all similar articles

Cited by 26 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback